Pathogenetic Therapy of Psoriasis by Muramyl Peptide

Psoriasis is a multifactorial disease with a dysregulation in immune system. The aim of this study was to survey the clinical efficacy and safety of muramyl peptide-the ligand of the receptors of innate immunity (drug Licopid, AO Peptek, Moscow, Russia) in patients with psoriasis. The effect of muramyl peptide on 86 patients with different severity of plaque psoriasis was tested. The Psoriasis Area and Severity Index (PASI), cytokine status and production of nitric oxide in blood serum, and the subsequent course of psoriasis have been evaluated. Evaluation of significance of observed differences was presented by the Student's t-test. As a result of the treatment, clinical cure or improvement was detected in 98.2% of patients (p < 0.05), while 24.4% had a complete cure. Subsequent observations during 4 years showed that patients who received muramyl peptide statistically significantly increased relapse-free period. Moreover, subsequent relapses of the disease after treatment with muramyl peptide were in much more milder form in the cases of mild psoriasis. The conducted studies showed that monotherapy with muramyl peptide stopped the clinical manifestations of psoriasis, normalized the processes of cytokine-dependent [interleukin (IL)-4, IL-10, IL-12, tumor necrosis factor alpha (TNF-alpha)] regulation of the immune response and nonspecific resistance, expressed in a decreasing amount of serum antigens sCD54 [soluble intercellular adhesion molecule-1 (sICAM-1)]to reference values (p <= 0.01). Taken together, our research demonstrated the effectiveness of therapy with muramyl peptide and moreover, that elevated levels of sCD54 and MIF (p <= 0.01) in the serum of patients with psoriasis considered as potential biomarkers of the severityof psoriasis and control over their dynamics have prognostic significance in determining the effectiveness of the therapy.

Authors
Guryanova S. 1, 2, 3 , Udzhukhu V.4 , Kubylinsky A.4
Journal
Frontiers in Immunology
Publisher
Frontiers Media S.A.
Language
English
Status
Published
DOI
10.3389/fimmu.2019.01275
Number
1275
Volume
10
Year
2019
Organizations
  • 1 RAS, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia
  • 2 RUDN Univ, Med Inst, Moscow, Russia
  • 3 AO Peptek, Moscow, Russia
  • 4 Pirogov Russian Natl Res Med Univ RNRMU, Moscow, Russia
Keywords
psoriasis; muramyl peptide; sCD54; MIF; IL-4; IL-10; IL-12; TNF-alpha
Date of creation
20.07.2021
Date of change
20.07.2021
Short link
https://repository.rudn.ru/en/records/article/record/74727/
Share

Other records

USE OF THE WHO ACCESS, WATCH, AND RESERVE CLASSIFICATION TO DEFINE PATTERNS OF HOSPITAL ANTIBIOTIC USE (AWARE): AN ANALYSIS OF PAEDIATRIC SURVEY DATA FROM 56 COUNTRIES

Article
Hsia Y.F., Lee B.R., Versporten A., Yang Y.H., Bielicki J., Jackson C., Newland J., Goossens H., Magrini N., Sharland M., Teston L., Cheung K., Koning S., Grimwood K., Cross J., Da Silva A., Benadof D., Zhang W.S., Zhao W., Liu G., Shen K.L., Yao K.H., Zheng Y.J., Deng J.K., Zhang J.S., Wang Y., Jiang X.Y., Tian D.Y., Jing C.M., Wang L.J., Cao S.C., Wu L.J., Chen X., Ding M.J., Zhang L., Lin L., Yang J.H., Cao Q., Wang W., Li J.P., Tang L.F., Liu J., Wang P., Qian J., Zhu C.M., Lu G., Deng Q.L., Mu X.P., Zhao C.A., Dong X.Y., Zhang H., Li C.Y., Li W., Saxen H., Kekomaki S., Hufnagel M., Rippberger B., Knuf M., Nikolic P., Hubner J., Kreitmeyer K., Behrends U., Rieber N., Renk H., Spyridis N., Tsolia M., Papaevangelous V., Gkentzi D., Syrogiannopoulos G., Kaffe K., Roilides E., Pitsava G., Papadimitriou E., Iosifidis E., Gandra S., Laxminarayan R., Alvarez-Uria G., Jinka D., Murki S., Kandraju H., Singh S., Vasudevan A.K., Kanithi R., Akula A., Chikkappa A., Tunga O., Subramanian S., Sharma A., Dharmapalan D., Ashkenazi-Hoffnung L., Ashkenazi S., Esposito S., Tagliabue C., Tersigni C., Galli L., D'Argenio P., Pansa P., Duse M., Horikoshi Y., Fukuoka K., Jimenez R., Ojeda K., Okokon I., Mahmood H., Gowin E., Slowinska-Jarzabek B., Majda-Stanislawska E., Sicinska J., Chan S.M., Chang A., Rozic M., Premru M., Finlayson H., Whitelaw A., Rabie H., Dramowski A., O'Connell N., Epalza C., Rojo-Conejo P., Torres F.M., Justicia A., Jian V., Cheng C.L., Lumbiganon P., Paopongsawan P., Puthanakit T., Anugulruengkitt S., Yarci E., Doerholt K., Vazouras K., Bamford A., Irwin A., Drysdale S.B., Collett-White F., Harkensee C., McMaster P., Green H., Rees S., Ledoare K., Chappell F., Jacqueline D., Hackett S., Vergnano S., Praveen S., Herberg J., Speirs L., Moriarty P., Lacej D., Hoxha I., Cornistein W., Quiros R., Hojman M., Del Castillo M., Ghazaryan L., AlSalman J., Konopnicki D., Pierard D., Holemans X., Schelstraete P., Firre E., Van Herendael B., Dedeic-Ljubovic A., Pignatari A., Sabuda D., Carvajal C., Alvaro R., Labarca J., Solano A., Ramirez C., Marekovic I., Horvatic J., Pristas I., Marshall E., Pagava K., Korinteli I., Neubert A., Enimil A., Frimpong J.A., Soltani J., Fitzgerald D., Kasahara K., Gu Y., Okinaka K., Kunishima H., Elhajji F.D., Alshehri M., Raka L., Kambaralieva B., Sviestina I., Burokiene S., Usonis V., Shaqiri E., Zarb P., Markovic G., Simovic S., Nwajiobi-Princewil P., Iregbu K., Aboderin A., Oduyebo O., Olayinka A., McCorry A., McCullagh B., Gormley C., Rachina S., Carevic B., Chen H.H., Ling M.L., Barrero P.T., Buijtels P., Van Elzakker E., Thompson S., Cooper M., Rios E., Hudson M., Greer N., Gessner-Wharton M., Gawrys G.
LANCET GLOBAL HEALTH. ELSEVIER SCI LTD. Vol. 7. 2019.